The award funds innovative but inherently risky research endeavors that have the potential to overturn existing scientific paradigms or create new ones.
Weill Cornell Medicine researchers have found that removing protected class regulation from Medicare prescription drug policies could greatly reduce the United States' prescription drug spending, potentially saving $47 billion between 2011 and 2019.
Weill Cornell Medicine researchers found that the possibility of parental disclosure through online patient portals led older adolescents to hesitate in sharing complete health information with doctors.
A mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma compared with other variants, according to a multicenter study conducted at Weill Cornell Medicine, NewYork-Presbyterian and other institutions.
A new study emphasizes the importance of considering sex differences in Alzheimer’s research – a step that could ultimately lead to more precise and effective treatments.
A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.
A new preclinical model using CRISPR has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.
A multi-institutional clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.
